The New Clinicopathologic and Molecular Findings in Myeloid Neoplasms With inv(3)(q21q26)/t(3;3)(q21;q26.2)
Authors:
- Huan-You WangHWHuan-You Wang
- Hooman H. RashidiHRHooman H. Rashidi
- 15 September 2016
- journal article
- review article
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 140 (12) , 1404-1410
Abstract
Context.—: Inv(3)(q21q26)/t(3;3)(q21;q26.2) is the most common form of genetic abnormality of the so-called 3q21q26 syndrome. Myeloid neoplasms with 3q21q26 aberrancies include acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and blast crisis of myeloproliferative neoplasms. Recent advances on myeloid neoplasms with inv(3)/t(3;3) with regard to clinicopathologic features and novel molecular or genomic findings warrant a comprehensive review on this topic. Objective.—: To review the clinicopathologic features and molecular as well as genomic alterations in myeloid neoplasms with inv(3)/t(3;3). Data Sources.—: The data came from published articles in English-language literature. Conclusions.—: At the clinicopathologic front, recent studies on MDS with inv(3)/t(3;3) have highlighted their overlapping clinicopathologic features with and similar overall survival to that of inv(3)/t(3;3)-harboring AML regardless of the percentage of myeloid blasts. On the molecular front, AML and MDS with inv(3)/t(3;3) exhibit gene mutations, which affect the RAS/receptor tyrosine kinase pathway. Furthermore, functional genomic studies using genomic editing and genome engineering have shown that the reallocation of the GATA2 distal hematopoietic enhancer to the proximity of the promoter of ectopic virus integration site 1 (EVI1) without the formation of a new oncogenic fusion transcript is the molecular mechanism underlying these inv(3)/t(3;3) myeloid neoplasms. Although the AML and MDS with inv(3)/t(3;3) are listed as a separate category of myeloid malignancies in the 2008 World Health Organization classification, the overlapping clinicopathologic features, similar overall survival, and identical patterns at the molecular and genomic levels between AML and MDS patients with inv(3)/t(3;3) may collectively favor a unification of AML and MDS with inv(3)/t(3;3) as AML or myeloid neoplasms with inv(3)/t(3;3) regardless of the blast count.Keywords
This publication has 50 references indexed in Scilit:
- Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activityJournal of Experimental Medicine, 2011
- Targeting a DNA Binding Motif of the EVI1 Protein by a Pyrrole–Imidazole PolyamideBiochemistry, 2011
- De novo acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): a clinicopathologic and cytogenetic study of an entity recently added to the WHO classificationLaboratory Investigation, 2011
- Expression and prognostic significance of different mRNA 5′‐end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission durationGenes, Chromosomes and Cancer, 2008
- An interphase fluorescence in situ hybridisation assay for the detection of 3q26.2/EVI1 rearrangements in myeloid malignanciesBritish Journal of Haematology, 2007
- Fluorescence in situ hybridization studies using BAC clones of the EVI1 locus in hematological malignancies with 3q rearrangementsCancer Genetics and Cytogenetics, 2006
- Regulation of the expression of the oncogene EVI1 through the use of alternative mRNA 5′-endsGene, 2005
- Comparative Expression Analysis of the Antagonistic Transcription Factors EVI1 and MDS1-EVI1 in Murine Tissues and duringin VitroHematopoietic DifferentiationBiochemical and Biophysical Research Communications, 1998
- The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivatorLeukemia, 1997
- Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell linesCell, 1988